Table 2. Study 2 Practice-Level Baseline Variables for Randomization
Practice-Level and Clinical Variables Obtained from EHR DataPractice-Level Variables for Randomization (n = 18 Practices)Differences Between Study Groups on Raw Variables*
Mean (SD)Minimum, MaximumOptimal Randomizations (n = 172)Remaining Randomizations (n = 1556)
FTE clinicians (n)3.8 (3.1)1, 121.0 (2.6)1.3 (3.2)
African American race (%)2.9 (3.7)<1, 15.01.2 (3.1)1.4 (3.1)
Hispanic ethnicity (%)16.6 (18.5)<1, 68.03.6 (10.7)3.9 (10.7)
Medicaid/Uninsured (%)13.8 (8.6)0, 30.01.8 (3.3)3.0 (7.5)
Have type 2 diabetes (%)34.9 (18.4)13.0, 1008.4 (15.3)9.1 (16.8)
HbA1c >9 (%)9.1 (7.5)0, 251.5 (4.8)2.4 (8.1)
Stage 4 CKD (%)6.7 (4.5)0, 15.6<1 (2.6)1.9 (5.6)
BP >130/80§ (%)58.1 (14.2)35.4, 1.05.7 (14.4)5.8 (18.0)
BP>140/90 mmHg (%)31.2 (11.6)0, 51.92.6 (6.2)4.5 (14.8)
Mean HbA1c7.02 (0.38)6.63, 7.880.05 (0.15)0.12 ( 0.33)
Mean eGFR49.4 (3.2)45.2, 59.40.7 (2.2)1.3 (4.0)
Mean systolic BP132.1 (3.8)124.7, 138.60.8 (2.5)1.6 (5.1)
• * Data are means (maximums).

• P < .01, optimal vs. remaining randomizations.

• P < .05, optimal vs. remaining randomizations.

• § Patients have either systolic blood pressure (BP) >130 or diastolic BP >80, or both.

• Patients have either systolic BP >140 or diastolic BP >90, or both.

• Includes diabetic patients only.

• CKD, chronic kidney disease; eGFR, estimate glomerular filtration rate; FTE, full-time equivalent; SD, standard deviation.